156 / 172
156
the Disease Activity Score. BARFOT study group. Better Anti-
rheumatic
Farmacotherapy.
Rheumatology
(Oxford)
2000;39:1031-6.
101. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z,
Greenstein A, Brown A, et al. Very early treatment with
infliximab in addition to methotrexate in early, poor-prognosis
rheumatoid arthritis reduces magnetic resonance imaging
evidence of synovitis and damage, with sustained benefit after
infliximab withdrawal: results from a twelve-month
randomized, double-blind, placebo-controlled trial. Arthritis
Rheum 2005;52:27-35.
102. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon
JM, Keystone E, et al. Radiographic changes in rheumatoid
arthritis patients attaining different disease activity states with
methotrexate monotherapy and infliximab plus methotrexate:
the impacts of remission and tumour necrosis factor blockade.
Ann Rheum Dis 2009;68:823-7.
103. van der Heijde D, Klareskog L, Boers M, Landewé R,
Codreanu C, Bolosiu HD, et al. Comparison of different
definitions to classify remission and sustained remission: 1
year TEMPO results. Ann Rheum Dis 2005;64:1582-7.
104. van der Heijde D, Klareskog L, Landewé R, Bruyn GA,
Cantagrel A, Durez P, et al. Disease remission and sustained
halting of radiographic progression with combination
etanercept and methotrexate in patients with rheumatoid
arthritis. Arthritis Rheum 2007;56:3928-39.
105. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ,
Robertson D, et al. Comparison of methotrexate monotherapy
with a combination of methotrexate and etanercept in active,
early, moderate to severe rheumatoid arthritis (COMET): a
randomised, double-blind, parallel treatment trial. Lancet
2008;372:375-82.
106. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF,
Chartash EK, Segurado OG. Long term efficacy and safety of